» Articles » PMID: 38762696

Generation of Induced Pluripotent Stem Cells from an Individual with Early Onset and Severe Hypertrophic Cardiomyopathy Linked to MYBPC3: C.772G > A Mutation

Overview
Journal Hum Cell
Publisher Springer
Specialty Cell Biology
Date 2024 May 18
PMID 38762696
Authors
Affiliations
Soon will be listed here.
Abstract

Hypertrophic cardiomyopathy (HCM) is frequently caused by mutations in the MYPBC3 gene, which encodes the cardiac myosin-binding protein C (cMyBP-C). Most pathogenic variants in MYPBC3 are either nonsense mutations or result in frameshifts, suggesting that the primary disease mechanism involves reduced functional cMyBP-C protein levels within sarcomeres. However, a subset of MYPBC3 variants are missense mutations, and the molecular mechanisms underlying their pathogenicity remain elusive. Upon in vitro differentiation into cardiomyocytes, induced pluripotent stem cells (iPSCs) derived from HCM patients represent a valuable resource for disease modeling. In this study, we generated two iPSC lines from peripheral blood mononuclear cells (PBMCs) of a female with early onset and severe HCM linked to the MYBPC3: c.772G > A variant. Although this variant was initially classified as a missense mutation, recent studies indicate that it interferes with splicing and results in a frameshift. The generated iPSC lines exhibit a normal karyotype and display hallmark characteristics of pluripotency, including the ability to undergo trilineage differentiation. These novel iPSCs expand the existing repertoire of MYPBC3-mutated cell lines, broadening the spectrum of resources for exploring how diverse mutations induce HCM. They additionally offer a platform to study potential secondary genetic elements contributing to the pronounced disease severity observed in this individual.

References
1.
Liu L, Shenoy S, Jahng J, Liu Y, Knowles J, Zhuge Y . Generation of two heterozygous MYBPC3 mutation-carrying human iPSC lines, SCVIi001-A and SCVIi002-A, for modeling hypertrophic cardiomyopathy. Stem Cell Res. 2021; 53:102279. PMC: 9393020. DOI: 10.1016/j.scr.2021.102279. View

2.
Ribeiro M, Martins S, Carvalho T, Furtado M, Sampaio Cabral J, Brito D . Generation of induced pluripotent stem cell lines from two unrelated individuals with familial hypertrophic cardiomyopathy carrying the MYBPC3 missense c.1484G>A mutation. Stem Cell Res. 2023; 74:103282. DOI: 10.1016/j.scr.2023.103282. View

3.
Pioner J, Vitale G, Steczina S, Langione M, Margara F, Santini L . Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human HCM. Circ Res. 2023; 132(5):628-644. PMC: 9977265. DOI: 10.1161/CIRCRESAHA.122.321956. View

4.
Girolami F, Olivotto I, Passerini I, Zachara E, Nistri S, Re F . A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2006; 7(8):601-7. DOI: 10.2459/01.JCM.0000237908.26377.d6. View

5.
Ojala M, Prajapati C, Polonen R, Rajala K, Pekkanen-Mattila M, Rasku J . Mutation-Specific Phenotypes in hiPSC-Derived Cardiomyocytes Carrying Either Myosin-Binding Protein C Or α-Tropomyosin Mutation for Hypertrophic Cardiomyopathy. Stem Cells Int. 2016; 2016:1684792. PMC: 4707351. DOI: 10.1155/2016/1684792. View